Imunon Inc (NASDAQ: IMNN) announces interim progression-free survival (PFS) and overall survival (OS) data with IMNN-001 in its Phase 1/2 OVATION 2 Study of intraperitoneal IMNN-001 in combination with neoadjuvant chemotherapy (NACT) for newly diagnosed with advanced epithelial ovarian, fallopian tube
BioLineRx Ltd (NASDAQ: BLRX) announced data from the single-arm pilot phase of the investigator-initiated CheMo4METPANC Phase 2 combination trial of motixafortide and gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone, in first-line
AstraZeneca Plc (NASDAQ: AZN), Bristol Myers Squibb & Co (NYSE: BMY), and Boehringer Ingelheim are willing to participate in the initial round of Medicare drug price negotiation
Gritstone Bio Inc (NASDAQ: GRTS) received a contract from the Biomedical Advanced Research and Development Authority (BARDA) to conduct a Phase 2b comparative study evaluating its self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus other viral targets to